Marché européen de la vessie sous-active, par type (pharmacothérapie, méthodes chirurgicales, dispositif d'assistance urétrale et thérapies par cellules souches et gènes), voie d'administration (orale, parentérale et autres), utilisateur final (hôpitaux, cliniques, instituts universitaires et de recherche, et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et autres) Tendances de l'industrie et prévisions jusqu'en 2029.
Analyse et perspectives du marché européen de la vessie sous-active
Le marché européen de la vessie sous-active est stimulé par des facteurs tels que l'augmentation des cas d'infections vésicales neurogènes , l'augmentation du financement de la recherche, le développement de nouvelles thérapies pour la vessie sous-active (UAB) et les produits en cours de développement qui augmentent sa demande, ainsi que l'augmentation des investissements en R&D conduisant à la croissance du marché. Actuellement, les dépenses de santé ont augmenté dans les pays développés et émergents, ce qui devrait créer un avantage concurrentiel pour les fabricants qui souhaitent développer des produits nouveaux et innovants. En outre, l'augmentation des dépenses de santé et la prévalence croissante des troubles de la vessie ont un effet positif sur le marché.
Cependant, le coût élevé du traitement empêche les patients de recourir à des solutions efficaces et de haute qualité. Par conséquent, le coût élevé des procédures de traitement a un impact négatif sur le coût global du traitement. De plus, les médicaments actuellement utilisés pour le traitement de l'UAB ne sont pas cliniquement satisfaisants du point de vue de l'efficacité et de la sécurité, ce qui conduit à la nécessité de développer de nouveaux agents thérapeutiques.
Le marché européen de la vessie sous-active devrait croître au cours de la période de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la présence de nouveaux médicaments en cours de développement. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D pour lancer de nouveaux produits sur le marché.
Toutefois, le coût élevé associé à la recherche et aux études devrait freiner la croissance du marché, ce qui peut avoir un impact supplémentaire sur le lancement de nouveaux produits sur le marché.
L’augmentation du nombre de programmes de R&D et la montée des partenariats public-privé pour faciliter les développements novateurs en faveur de traitements innovants et efficaces influencent davantage le marché.
Europe underactive bladder market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
Europe underactive bladder market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyzes that Europe underactive bladder market will grow at a CAGR of 4.5% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) |
|
Countries Covered |
Germany, France, U.K, Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Poland, Turkey, Austria, Hungary, Norway, Ireland, Luxembourg, Lithuania, and rest of Europe |
|
Market Players Covered |
Astellas Pharma Inc., Aurobindo Pharma., Boehringer Ingelheim International GmbH, Macleods Pharmaceuticals Ltd., Orion Corporation, ONO PHARMACEUTICAL CO., LTD., Novartis AG, Pfizer Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Almirall, S.A, Glenwood, Vesiflo, Inc., and Alkem Labs. among others |
Market Definition
Underactive Bladder (UAB) is a clinical condition in which urination disorder is developed as a result of reduction in the contraction of the detrusor muscle (a muscle of the bladder) during urination. It is characterized by the feeling of having to urinate immediately, and thus, this condition is different from the Overactive Bladder (OAB). The present invention provides a pharmaceutical composition useful for the prevention or treatment of UAB which has an effect of improving the urinary flow rate, an effect of improving the overdistension of the bladder (an effect of reducing bladder capacity), and is therefore, useful for the prevention or treatment of UAB.
Moreover, it is a disease state which is different from the OAB characterized by urinary urgency which has been attracting attention in recent years. Causes of UAB include autonomic neuropathy such as diabetes and alcoholism, pelvic surgery such as radical hysterectomy and radical rectal cancer, spinal cord diseases such as spina bifida, and disc herniation is also known. Patients suffering from severe and mild bladder disorder-associated problems need pharmacotherapy often cycled with multiple therapies and without adequate relief receiving continued treatments, which also creates an impact on healthcare expenditure.
Europe Underactive Bladder Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:
Drivers
- Increasing prevalence of neurological disorder
UAB is a common neurological condition in which nerves and muscles do not work together very well resulting in prolonged urination time with or without a sensation of incomplete bladder emptying. In this condition, the detrusor muscles underperform for their contraction activity which is characterized by a slow urinary stream, hesitancy, and straining to void, with or without a feeling of incomplete bladder emptying, sometimes with storage symptoms even. Thus, the bladder either does not empty or empties only partially which is due to the bladder muscles being unable to release urine properly.
As a result, patients with UAB may have various urination symptoms and may be accompanied by a large amount of residual urine. Complications of urinary retention due to aggravation and Urinary Tract Infections (UTIs) due to chronic residual urine are often seen and have become a problem. Moreover, it is a disease state which is different from the OAB characterized by urinary urgency which has been attracting attention in recent years. Thus, the increasing prevalence of neurogenic bladder disorders is expected to drive market growth. This will lead to an increased demand for treatment that can detect patients as well, due to which there will be expected lucrative growth in the market.
- Rising healthcare expenditure
The instruments, manpower, and medical management in case of any harm to researchers, insurance, transportation, ethics committee fee, data processing, and other consumables lead to major cost involvement for the market players. The healthcare expenditure comprises all healthcare services, testing devices, family planning activities, and emergency aid designated for health. National Health Accounts provide many indicators based on expenditure collected within an internationally recognized framework. The factors determining any country's healthcare expenditure are income (per capita GDP), technological progress and variation in medical practice, and health systems characteristics.
The rise in healthcare expenditure simultaneously helps healthcare organizations and government bodies increase the research activities on menopause drugs, their upcoming clinical trials, and R&D activities. Also, the cost involved in the production and manufacturing of the new products, the market players require adequate allocation of funds and resources, hence, the government acts as a helping hand in this scenario. Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favorable factor. Hence, rising healthcare expenditure is expected to drive market growth in the future.
Opportunity
- Rising urologic complications of diabetes
One of the known causes of UAB includes autonomic neuropathy such as diabetes. Moreover, diabetes is associated with an earlier onset and increased severity of urologic diseases that result in costly and debilitated urologic complications. These urologic complications, including bladder dysfunction and UTIs among others, have a profound effect on the quality of life of both men and women with diabetes. Diabetes and urologic diseases are very common health problems that markedly increase in prevalence and incidence with advancing age. Urologic complications of diabetes are an immediate effect. Diabetes is the most prominent disorder and has a high prevalence globally.
Diabetes-associated bladder complications can be due to an alternation in the detrusor smooth muscles, neuronal dysfunction, and urothelial dysfunction. Depending on the nerves involved, the effects of diabetic neuropathy can range from discomfort and numbness in the legs to complications with the digestive system, the urinary tract, the blood vessels, and the core. The rising data on diabetes will significantly increase the risk of urologic complications of diabetes worldwide. Thus, it is required to recommend future directions for research and clinical care for proper treatment of urologic complications of diabetes. Support from other organizations would also be required to reach the under-developed regions to tackle the neglected complications. Therefore, this signifies that the rise in urologic complications of diabetes is expected to act as an opportunity for market growth.
Restraint/Challenge
- High cost of Research and Development (R&D)
R&D is a prerequisite in modifying the procedure intended to treat different kinds of patients. The higher cost of R&D for new products demands deep research and clinical studies. The various clinical phases in R&D require huge investments which can affect market growth. The research cost involved in planning and execution of the studies, and research requires adequate allocation of funds and resources, which can affect new developments in the market. The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased.
The high cost of the procedure is due to various checkpoints of treatments along with the use of high-tech modalities to perform such procedures. As cost of R&D for treatments is too high, it restricts accommodating high-quality and effective solutions. Henceforth, the high cost negatively impacts the cost of overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that the high cost associated with the research and studies is expected to restrain market growth which can further impact the launch of new products in the market.
Post-COVID-19 Impact on Europe Underactive Bladder Market
COVID-19 has positively affected in the growth of the market as there is rise in the demand for products widely in the region. People have become more health conscious as there is rising prevalence of various bladder diseases in the region. Complications of urinary retention due to aggravation and UTIs due to chronic residual urine are often seen and have become a problem. Hence, COVID-19 has impacted positively on this market.
Recent Developments
- In June 2020, Vesiflo, Inc. announced the medicare coverage of inFlow urinary prosthesis, a magnetically coupled FDA-approved intraurethral valve-pump device which can be used for 29 days by adult women as an alternative to intermittent catheterization. This results in a contribution to the expansion of product business quickly with commercialization in the market.
- In April 2020, Astellas Pharma Europe Ltd. completed a clinical trial that was conducted on subjects for the treatment of underactive bladder. Currently, ASP8302 is under phase-2 clinical trial to investigate the safety and tolerability of the drug in patients with underactive bladder.
Europe Underactive Bladder Market Scope
Europe underactive bladder market is categorized into four notable segments based on type, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Pharmacotherapy
- Surgical Methods
- Urethral Assist Device
- Thérapies à base de cellules souches et de gènes
En fonction du traitement, le marché est segmenté en pharmacothérapie, méthodes chirurgicales, dispositifs d’assistance urétrale et thérapies par cellules souches et gènes.
Voie d'administration
- Oral
- Parentérale
- Autres
En fonction de la voie d’administration, le marché est segmenté en voie orale, parentérale et autres.
Utilisateur final
- Hôpitaux
- Cliniques
- Instituts universitaires et de recherche
- Autres
En fonction de l’utilisateur final, le marché est segmenté en hôpitaux, cliniques, instituts universitaires et de recherche, et autres.
Canal de distribution
- Pharmacie de l'hôpital
- Pharmacie de détail
- Autres
En fonction du canal de distribution, le marché est segmenté en pharmacie hospitalière, pharmacie de détail et autres.
Analyse/perspectives régionales du marché de la vessie sous-active en Europe
Le marché européen de la vessie sous-active est analysé et des informations et tendances sur la taille du marché sont fournies par type, voie d’administration, utilisateur final et canal de distribution comme référencé ci-dessus.
Les pays couverts dans le rapport sur le marché européen de la vessie sous-active sont l'Allemagne, la France, le Royaume-Uni, l'Italie, la Russie, l'Espagne, la Turquie, les Pays-Bas, la Suisse, la Pologne, la Turquie, l'Autriche, la Hongrie, la Norvège, l'Irlande, la Lituanie et le reste de l'Europe.
- En 2022, le marché européen de la vessie sous-active devrait croître en raison de la prévalence croissante des troubles de la vessie et de la croissance de la population gériatrique. Les avancées technologiques dans le traitement des troubles de la vessie et l'augmentation des approbations de produits stimulent également la croissance du marché.
L’Allemagne devrait dominer le marché en raison de la présence de grands acteurs et d’un système de santé établi pour traiter les troubles de la vessie.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces du porteur et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des tarifs nationaux et des routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du marché européen de la vessie sous-active
Le paysage concurrentiel du marché européen des vessies sous-actives fournit des détails par concurrents. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché européen des vessies sous-actives.
Certains des principaux acteurs opérant sur le marché sont
- Astellas Pharma Inc.
- Aurobindo Pharma.
- Boehringer Ingelheim International GmbH
- Macleods Pharmaceutiques Ltée.
- Société Orion
- ONO PHARMACEUTIQUE SOCIÉTÉ, LTD.
- Novartis SA
- Pfizer Inc.
- Cipla Inc.
- Laboratoires Dr. Reddy's Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltée.
- Almirall, SA
- Glenwood
- Laboratoires Alkem.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'Europe par rapport au pays et l'analyse des parts des fournisseurs. Veuillez demander un appel à l'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE UNDERACTIVE BLADDER MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-
4.4.1 DOXAZOSIN
4.4.2 BETHANECHOL CHLORIDE
4.4.3 TAMSULOSIN HYDROCHLORIDE
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER
4.5.1 EU CLINICAL TRIALS REGISTER-
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:
4.8 CROSS-BORDER DEALS:
4.9 OUTLOOK FOR 2022:
4.1 PATIENT ENROLMENT STRATEGIES
4.11 FACTORS AFFECTING PATIENT RECRUITMENT:
4.12 CHALLENGES:
4.13 PATIENT FUNNEL ANALYSIS:
4.14 RECOMMENDATIONS
4.14.1 USE OF TECHNOLOGY:
4.14.2 PARTICIPANT CHARACTERISTICS:
4.14.3 RECRUITER CHARACTERISTICS:
4.14.4 SYSTEMS & PROCEDURES:
4.14.5 LOCATION:
4.14.6 NATURE OF RESEARCH:
4.15 CONCLUSION:
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM
4.17 WHAT CAUSES UNDERACTIVE BLADDER?
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-
5 EUROPE UNDERACTIVE BLADDER MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO
6.1.4 RISING HEALTHCARE EXPENDITURE
6.2 RESTRAINTS
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.3 OPPORTUNITIES
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
6.4 CHALLENGES
6.4.1 LACK OF PROPER TREATMENT
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER
7 EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE
7.1 OVERVIEW
7.2 PHARMACOTHERAPY
7.2.1 ALPHA-BLOCKERS
7.2.2 MUSCARINIC AGONISTS
7.2.3 CHOLINESTERASE INHIBITOR
7.2.3.1 BY DRUGS
7.2.3.1.1 TAMSULOSIN
7.2.3.1.2 DOXAZOSIN
7.2.3.1.3 DISTIGMINE
7.2.3.1.4 BETHANECHOL
7.2.3.1.5 OTHERS
7.2.4 BY PRODUCT TYPES
7.2.4.1 GENERICS
7.2.4.2 BRANDED
7.2.4.2.1 FLOMAX
7.2.4.2.2 ALFADIL
7.2.4.2.3 GRAVITOR
7.2.4.2.4 URIVOID
7.2.4.2.5 OTHERS
7.3 SURGICAL METHODS
7.3.1 SURGICAL NERVE STIMULATION
7.3.2 REDUCTION CYSTOPLASTY
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION
7.3.4 INJECTION INTO EXTERNAL SPHINCTER
7.3.5 OTHERS
7.4 URETHRAL ASSIS DEVICE
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP
7.5 STEM CELL AND GENE THERAPIES
7.5.1 NERVE GROWTH FACTOR
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS
8 EUROPE UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.3 ORAL
8.4 OTHERS
9 EUROPE UNDERACTIVE BLADDER MARKET , BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 ACADEMIC AND RESEARCH
9.5 OTHERS
10 EUROPE UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 OTHERS
11 EUROPE UNDERACTIVE BLADDER MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 RUSSIA
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 NETHERLANDS
11.1.9 SWITZERLAND
11.1.10 POLAND
11.1.11 AUSTRIA
11.1.12 HUNGARY
11.1.13 NORWAY
11.1.14 IRELAND
11.1.15 LITHUANIA
11.1.16 REST OF EUROPE
12 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NOVARTIS AG
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ASTELLAS PHARMA INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ORION CORPORATION.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ALKEM LABS.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 ALMIRALL, S.A
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 AUROBINDO PHARMA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CIPLA INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GLENWOOD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MACLEODS PHARMACEUTICALS LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ONO PHARMACEUTICAL CO., LTD.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 VESIFLO, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET
TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET
TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY
TABLE 4 TOTAL 58 DRUGS DISCONTINUED
TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY
TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-
TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-
TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:
TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 10 EUROPE UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)
TABLE 28 EUROPE HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 33 EUROPE HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 39 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 40 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 41 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 42 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 43 EUROPE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 44 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 46 EUROPE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 47 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 48 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 49 EUROPE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 EUROPE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 51 EUROPE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 52 EUROPE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 53 GERMANY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 55 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 56 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 GERMANY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 62 GERMANY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 63 GERMANY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 64 GERMANY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 GERMANY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 GERMANY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 67 GERMANY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 68 GERMANY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 69 FRANCE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 71 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 73 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 74 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 75 FRANCE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 FRANCE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 FRANCE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 FRANCE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 FRANCE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 82 FRANCE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 83 FRANCE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 84 FRANCE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 85 U.K. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 88 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 89 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 90 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 91 U.K. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 92 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 94 U.K. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 95 U.K. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 96 U.K. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 U.K. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 U.K. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 99 U.K. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 100 U.K. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 101 ITALY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 103 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 106 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 107 ITALY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 108 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 109 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 110 ITALY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 111 ITALY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 112 ITALY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 113 ITALY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 114 ITALY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 115 ITALY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 116 ITALY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 117 RUSSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 119 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 120 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 121 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 122 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 123 RUSSIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 124 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 125 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 126 RUSSIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 127 RUSSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 128 RUSSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 129 RUSSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 130 RUSSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 131 RUSSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 132 RUSSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 133 SPAIN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 135 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 136 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 137 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 138 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 139 SPAIN BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 140 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 141 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 142 SPAIN BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 143 SPAIN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 144 SPAIN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 145 SPAIN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 146 SPAIN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 147 SPAIN UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 148 SPAIN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 149 TURKEY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 151 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 152 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 153 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 154 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 155 TURKEY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 156 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 157 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 158 TURKEY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 159 TURKEY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 160 TURKEY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 161 TURKEY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 162 TURKEY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 163 TURKEY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 164 TURKEY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 165 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 167 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 168 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 169 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 170 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 171 NETHERLANDS BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 172 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 173 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 174 NETHERLANDS BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 175 NETHERLANDS SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 176 NETHERLANDS URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 177 NETHERLANDS STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 178 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 179 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 180 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 181 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 182 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 183 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 184 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 185 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 186 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 187 SWITZERLAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 188 SWITZERLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 189 SWITZERLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 190 SWITZERLAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 191 SWITZERLAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 192 SWITZERLAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 193 SWITZERLAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 194 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 195 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 196 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 197 POLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 POLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 199 POLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 200 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 201 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 202 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 203 POLAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 204 POLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 205 POLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 206 POLAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 207 POLAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 208 POLAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 209 POLAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 210 POLAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 211 POLAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 212 POLAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 213 AUSTRIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 AUSTRIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 215 AUSTRIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 216 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 217 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 218 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 219 AUSTRIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 220 AUSTRIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 221 AUSTRIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 222 AUSTRIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 223 AUSTRIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 224 AUSTRIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 225 AUSTRIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 226 AUSTRIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 227 AUSTRIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 228 AUSTRIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 229 HUNGARY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 HUNGARY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 231 HUNGARY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 232 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 233 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 234 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 235 HUNGARY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 236 HUNGARY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 237 HUNGARY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 238 HUNGARY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 239 HUNGARY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 240 HUNGARY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 241 HUNGARY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 242 HUNGARY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 243 HUNGARY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 244 HUNGARY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 245 NORWAY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 NORWAY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 247 NORWAY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 248 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 249 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 250 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 251 NORWAY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 252 NORWAY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 253 NORWAY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 254 NORWAY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 255 NORWAY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 256 NORWAY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 257 NORWAY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 258 NORWAY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 259 NORWAY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 260 NORWAY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 261 IRELAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 IRELAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 263 IRELAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 264 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 265 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 266 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 267 IRELAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 268 IRELAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 269 IRELAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 270 IRELAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 271 IRELAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 272 IRELAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 273 IRELAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 274 IRELAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 275 IRELAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 276 IRELAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 277 LITHUANIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 278 LITHUANIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 279 LITHUANIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 280 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 281 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 282 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 283 LITHUANIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 284 LITHUANIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 285 LITHUANIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 286 LITHUANIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 287 LITHUANIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 288 LITHUANIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 289 LITHUANIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 290 LITHUANIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 291 LITHUANIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 292 LITHUANIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 293 REST OF EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 2 EUROPE UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE UNDERACTIVE BLADDER MARKET: DROC ANALYSIS
FIGURE 4 EUROPE UNDERACTIVE BLADDER MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE EUROPE UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD
FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UNDERACTIVE BLADDER MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE UNDERACTIVE BLADDER MARKET
FIGURE 14 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, 2021
FIGURE 15 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)
FIGURE 17 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE
FIGURE 18 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 19 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 21 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, 2021
FIGURE 23 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)
FIGURE 25 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 27 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 29 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 EUROPE UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)
FIGURE 31 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)
FIGURE 32 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 EUROPE UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)
FIGURE 35 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
